Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2a + ribavirin (Roche)
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Peginterferon alfa-2a + ribavirin is a combination therapy formerly used as the standard of care for chronic hepatitis C virus (HCV) infection. The regimen consists of peginterferon alfa-2a, a pegylated recombinant interferon, and ribavirin, a synthetic guanosine analog. Peginterferon alfa-2a binds to the cell surface interferon-alpha receptors (IFNAR1 and IFNAR2), activating the JAK-STAT signaling pathway and inducing the expression of interferon-stimulated genes that establish an antiviral state. Ribavirin is a broad-spectrum antiviral that likely exerts its effects through multiple mechanisms, including the inhibition of viral RNA-dependent RNA polymerase, induction of lethal mutagenesis in the viral genome, and inhibition of host inosine monophosphate dehydrogenase (IMPDH), which depletes intracellular guanosine triphosphate pools. While highly effective compared to non-pegylated interferon, this combination has largely been replaced by direct-acting antiviral (DAA) regimens due to superior efficacy and a more favorable side-effect profile.
- Brand names
- PegasysCopegusRebetol
- Other names
- peg-interferon alpha-2a + ribavirinpeginterferon alfa-2a and ribavirinpegylated interferon alfa-2a + ribavirin
02
Targets
RdRp (Coronavirus RNA-dependent RNA polymerase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)IFNAR1 (Interferon alpha/beta receptor 1)EIF4E (Eukaryotic translation initiation factor 4E)VCE (Viral mRNA capping enzyme complex)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on peginterferon alfa-2a + ribavirin (Roche).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2a + ribavirin (Roche).